X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (783) 783
Publication (80) 80
Newspaper Article (30) 30
Book Review (26) 26
Newsletter (18) 18
Magazine Article (7) 7
Book Chapter (5) 5
Trade Publication Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (589) 589
humans (555) 555
hepatitis c virus (431) 431
hepatitis c (401) 401
antiviral agents - therapeutic use (353) 353
hepatitis c, chronic - drug therapy (322) 322
ribavirin (308) 308
sofosbuvir (298) 298
hepacivirus - genetics (296) 296
hepatitis (283) 283
genotype (259) 259
hepacivirus - drug effects (255) 255
interferon (254) 254
protease inhibitors (238) 238
drug therapy, combination (226) 226
gastroenterology & hepatology (221) 221
male (204) 204
pharmacology & pharmacy (196) 196
female (195) 195
middle aged (185) 185
treatment outcome (180) 180
treatment-naive patients (171) 171
antiviral agents (166) 166
hepatitis c - drug therapy (163) 163
infection (161) 161
virus diseases (157) 157
hcv (153) 153
infections (152) 152
sustained virological response (149) 149
hepatitis c, chronic - virology (147) 147
genotype & phenotype (146) 146
health aspects (146) 146
antiviral agents - adverse effects (143) 143
viruses (143) 143
drug therapy (140) 140
therapy (135) 135
aged (133) 133
antiviral agents - pharmacology (133) 133
adult (132) 132
care and treatment (128) 128
antiviral agents - administration & dosage (126) 126
ribavirin - therapeutic use (126) 126
genotype 1 infection (119) 119
viral nonstructural proteins - antagonists & inhibitors (119) 119
proteases (118) 118
cirrhosis (117) 117
virology (116) 116
patients (115) 115
daclatasvir (113) 113
plus ribavirin (110) 110
virus-infection (110) 110
infectious diseases (109) 109
ledipasvir (103) 103
protease inhibitor (102) 102
direct-acting antivirals (101) 101
genetic aspects (100) 100
microbiology (100) 100
digestive system diseases (98) 98
pegylated interferon (98) 98
research (97) 97
genotypes (96) 96
liver (95) 95
liver cirrhosis (95) 95
drug resistance, viral (94) 94
inhibitor (93) 93
biological response modifiers (92) 92
hepatology (89) 89
hepatitis c - virology (88) 88
ns5a inhibitor (88) 88
protease inhibitors - therapeutic use (87) 87
telaprevir (87) 87
simeprevir (85) 85
genotype 1 (84) 84
gastroenterology and hepatology (83) 83
medicine (83) 83
liver diseases (80) 80
multidisciplinary sciences (80) 80
hepatitis-c virus (78) 78
uridine monophosphate - analogs & derivatives (78) 78
drug resistance (75) 75
analysis (72) 72
imidazoles - therapeutic use (68) 68
research article (68) 68
viral nonstructural proteins - genetics (68) 68
interferon-alpha - therapeutic use (66) 66
sofosbuvir - therapeutic use (66) 66
science (65) 65
open-label (64) 64
ribavirin - administration & dosage (64) 64
treatment-naive (64) 64
combination (63) 63
abridged index medicus (62) 62
resistance (62) 62
antiviral therapy (61) 61
double-blind (61) 61
mutation (61) 61
inhibitors (60) 60
young adult (60) 60
gastroenterology (59) 59
treatment-experienced patients (59) 59
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 16, pp. 1560 - 1561
Journal Article
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 2, pp. 419 - 429
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 11/2014, Volume 21, Issue 11, pp. 762 - 768
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 3, pp. 736 - 743.e1
Journal Article
Journal Article